OraSure Technologies, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023, compared with FY2022. Although the request identifies 2023 Q4, the supplied filing reports annual results; it does not provide a clear standalone fourth-quarter financial summary in the supplied text.
Business context
OraSure develops and sells rapid diagnostic tests, specimen-collection products, and related laboratory and bioinformatics services. Its products include COVID-19, HIV and hepatitis C tests, drug-testing products, and genomic and microbiome sample-management solutions. In February 2023, the company combined its Diagnostics and Molecular Solutions operations under one reporting hierarchy.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net revenue | $405.5 million | $387.5 million |
| Gross profit / gross margin | $171.7 million / 42% | $148.4 million / 38% |
| Operating income (loss) | $32.7 million | ($22.2 million) |
| Net income (loss) | $53.7 million | ($17.1 million) |
| Diluted earnings (loss) per share | $0.72 | ($0.24) |
| Cash provided by (used in) operating activities | $141.6 million | ($47.2 million) |
- Revenue rose 5%. COVID-19 diagnostics revenue increased 10% to $257.5 million; HIV diagnostics revenue increased, while molecular sample-management, molecular-services and COVID-19 collection-kit revenues declined.
- COVID-19 diagnostics represented 64% of FY2023 revenue. InteliSwab revenue was $257.5 million, versus $233.7 million in FY2022. OraQuick HIV revenue increased to $60.8 million from $38.8 million.
- Gross margin improved with higher InteliSwab sales, manufacturing efficiencies, a packaging change and lower scrap, partly offset by $6.9 million of accelerated depreciation related to winding down Thailand manual assembly and $0.5 million related to a warehouse exit.
- Operating expenses, excluding impairment charges, fell $25.4 million to $128.2 million, reflecting cost reductions and lower headcount. Reported impairment losses were $10.8 million, compared with $17.1 million in FY2022.
- Other income was $23.6 million, including $12.8 million of additional profit recognized when the fixed-price $109 million U.S. government manufacturing-capacity contract was completed. This contract-related income materially contributed to the return to profitability.
- At year-end, cash and cash equivalents were $290.4 million; short-term investments were zero, versus $26.9 million in FY2022. Working capital was $346.9 million. No borrowings are shown on the balance sheet; lease liabilities totaled approximately $13.5 million.
- Cash from operations benefited from inventory reductions of $48.2 million and accounts-receivable collections of $31.1 million, including collections related to InteliSwab shipments. Cash increased $206.4 million during the year.
- Total assets were $482.8 million, total liabilities $52.2 million, and stockholders’ equity $430.7 million. Inventory fell to $47.6 million from $95.7 million.
Material changes, outlook and notable items
- Management expects a significant decline in InteliSwab revenue in 2024, citing completion of government procurement contracts and lower overall COVID-19 testing demand. The filing provides no specific revenue or earnings guidance.
- One customer accounted for approximately 63% of FY2023 net revenue, compared with 58% in FY2022, creating substantial customer-concentration exposure.
- Molecular sample-management revenue decreased 14% to $54.3 million. Molecular-services revenue fell 39% to $4.5 million, attributed to lost customers and completion of clinical studies without replacement work. COVID-19 molecular collection-kit revenue declined 97% to $0.3 million.
- OraSure recorded $8.5 million of intangible-asset impairment and $2.3 million of impairment on idle equipment. A developed-technology asset was written off after failed stability studies and the decision to discontinue that technology.
- In early 2024, the company told BARDA it would not pursue further development of an InteliSwab product intended to obtain 510(k) clearance and a CLIA waiver. Development of a second-generation Ebola test with BARDA funding continued.
- The company had funded $28.3 million of a planned investment in Sapphiros by February 2024, with up to $1.7 million more committed subject to conditions. Management expects the relationship and distribution agreements to broaden its product offerings; benefits are not assured.
- About $84.9 million, or 29% of cash and cash equivalents, was held by the Canadian subsidiary. Management intends to continue permanently reinvesting historical foreign-subsidiary earnings; additional repatriation could create tax costs.
- In 2023, a material weakness in customer-pricing controls was identified after an inaccurate price affected revenue recognition in the first half. The filing says the error was not material and the weakness was remediated by year-end. The company also corrected an immaterial FY2022 vendor-rebate accounting error.
- In patent litigation with Spectrum Solutions, the district court had ruled against OraSure on noninfringement; OraSure’s appeal was pending. In February 2024, the PTO held certain claims of a second patent unpatentable, and the company was considering appellate options.
Key risks and contingencies
- COVID-19 sales and government procurement contributed heavily to revenue and cash generation; weaker demand or fewer contracts could materially affect results.
- Concentrated customer exposure, public-health funding dependence, variable customer ordering, and competitive pricing may affect revenue and margins.
- OraSure depends on third parties and sole-source suppliers for certain critical components and products. Supply disruption, manufacturing-quality issues, or regulatory delays could interrupt sales.
- Products face extensive FDA and international regulatory requirements. The FDA’s proposed regulation of laboratory-developed tests could raise costs or reduce demand for customers’ testing and related collection products.
- Other risks include execution of the Sapphiros relationship, intellectual-property disputes, foreign-exchange movements, inflation, cybersecurity and privacy incidents, and the company’s ability to sustain profitability. The U.S. deferred-tax-asset valuation allowance remained in place.
- The company reported $1.0 million of estimated penalties accrued for vendor minimum-purchase commitments, based on current forecasts. Management said ordinary-course legal matters were not expected to have a material adverse effect, while the Spectrum dispute remained active.
Most important facts for investors to verify
- How much FY2024 revenue and cash generation depends on InteliSwab and government contracts, and whether other product lines can offset the expected decline.
- The identity, purchasing commitments, receivable exposure and ongoing demand of the customer responsible for 63% of FY2023 revenue.
- Whether FY2023 operating cash flow and profitability are repeatable without the working-capital release and $12.8 million government-contract profit.
- The return prospects, total funding obligation, and commercial milestones associated with the Sapphiros investment and distribution agreements.
- Whether inventory levels, impairment charges, vendor commitments and manufacturing capacity are aligned with current demand forecasts.
- Developments in the Spectrum patent proceedings, regulatory requirements and remediation of the customer-pricing control weakness.